

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Takeda UK (brentuximab vedotin) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • African Caribbean Leukaemia Trust • Anthony Nolan • Black Health Agency for Equality • Blood Cancer UK • Cancer Black Care • Cancer Equality • Cancer52 • DKMS • Follicular Lymphoma Foundation • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia Care • Lymphoma Action • Macmillan Cancer Support • Maggie's Centres • Marie Curie • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • WMUK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatrics Society • British Institute of Radiology 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare Limited (doxorubicin) • Hospira (vinblastine) • Janssen-Cilag Ltd (doxorubicin) • Kyowa Kirin Ltd (bleomycin) • Medac GmbH (dacarbazine, doxorubicin) • Pfizer Limited (doxorubicin) • Seacross Pharmaceuticals Ltd (doxorubicin) • Teva Pharma B.V. (doxorubicin)

Provisional stakeholder list for the proposed technology appraisal of brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

Issue date: November 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Oncology Pharmacy Association • British Psychosocial Oncology Society • British Society for Haematology • British Transplantation Society • Cancer Research UK • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society • United Kingdom Cutaneous Lymphoma Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Haematological Malignancies Group • Cochrane UK • Genomics England • Institute of Cancer Research • Leukaemia Busters • Leukaemia UK • Lymphoma Research Trust • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.